Brief: Syros Receives FDA Orphan Drug Designation For SY-5609

Syros Pharmaceuticals

13/09/2022 21:04

Sept 13 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SY-5609 FOR
THE
TREATMENT OF PANCREATIC CANCER
    * SYROS PHARMACEUTICALS INC- SAFETY AND CLINICAL ACTIVITY
DATA
FROM SAFETY LEAD-IN PORTION OF TRIAL ARE EXPECTED IN SECOND HALF
OF 2022
    * SYROS PHARMA - UNDER CLINICAL SUPPLY DEAL WITH ROCHE,
SYROS
SUPPLYING SY-5609 FOR COMBINATION DOSING COHORT IN ROCHE'S PHASE
1/1B INTRINSIC TRIAL

Source text for Eikon:  ID:nBw953dgya 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))